Navigation Links
Replidyne Announces 2007 Fourth Quarter and Full Year Results
Date:2/26/2008

p://www.Replidyne.com" target="_new">http://www.Replidyne.com and go to the Investor Relations section.

A replay of the conference call will be available approximately one hour after the completion of the call through Tuesday, March 11, 2008 at midnight. Callers may access the replay by dialing 888-286-8010 (U.S. participants) or 617-801-6888 (international participants). The audio replay passcode is 92464480. To access a replay of the webcast, visit the Investor Relations section of the Company's website at http://www.Replidyne.com.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; th
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for the ... Tech Awards. , Now in its 22nd year, this premier awards event celebrates the ... the nation and around the world. The OC Tech Alliance will announce all winners ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
Breaking Biology Technology:Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3
... by Strong Revenue Growth, Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), ... Q1 2008 (millions) Q1 2007 Comparison ... 164.5% increase Naglazyme Net Product Revenue ... Aldurazyme (net sales by Genzyme) $36.8 ...
... ... - Product revenues increased 30% to a record $59.7 million ... 28,600 new pulse oximeters ... April 29, 2008 Masimo,Corporation (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion ...
... transmit medical images via cellular phones that has ... researcher has the potential to provide sophisticated radiological diagnoses ... lacking access to such technology. This would include millions ... areas of developed countries who live considerable distances from ...
Cached Biology Technology:BioMarin Announces First Quarter 2008 Financial Results 2BioMarin Announces First Quarter 2008 Financial Results 3BioMarin Announces First Quarter 2008 Financial Results 4BioMarin Announces First Quarter 2008 Financial Results 5BioMarin Announces First Quarter 2008 Financial Results 6BioMarin Announces First Quarter 2008 Financial Results 7BioMarin Announces First Quarter 2008 Financial Results 8BioMarin Announces First Quarter 2008 Financial Results 9BioMarin Announces First Quarter 2008 Financial Results 10BioMarin Announces First Quarter 2008 Financial Results 11Masimo Reports First Quarter 2008 Financial Results 2Masimo Reports First Quarter 2008 Financial Results 3Masimo Reports First Quarter 2008 Financial Results 4Masimo Reports First Quarter 2008 Financial Results 5Masimo Reports First Quarter 2008 Financial Results 6Masimo Reports First Quarter 2008 Financial Results 7Masimo Reports First Quarter 2008 Financial Results 8Masimo Reports First Quarter 2008 Financial Results 9Masimo Reports First Quarter 2008 Financial Results 10Researchers develop method for transmitting medical images via cell phones 2Researchers develop method for transmitting medical images via cell phones 3Researchers develop method for transmitting medical images via cell phones 4
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... from the University of Santiago de Compostela (USC) have ... The results show that the principal goal of young ... The most antisocial among them place greater importance on ... most importance on are to do with leaving home, ...
... Research currently being undertaken at the University of ... Abdominal Aortic Aneurysms (AAA) in men. In her ... into the causes of the male predominance of AAA, ... disease. Preliminary results from the study will be showcased ...
... KNOXVILLE -- By examining 800,000-year-old polar ice, scientists increasingly are ... melt and that carbon dioxide has become more abundant in ... Jrme Chappellaz has been examining ice cores collected from deep ... studies on the interconnecting air spaces of old snow -- ...
Cached Biology News:Teenagers want to finish their studies and leave home 2Increased likelihood of male death from disease 2Scientist links increase in greenhouse gases to changes in ocean currents 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: